Home » Robert Friel

Robert Friel

Jan 31, 2008
Premium
Newly appointed PerkinElmer CEO Robert Friel’s salary for 2008 will increase to $875,000, according to a document filed with the US Securities and Exchange Commission last week.
 
Last week, the company announced Friel had been appointed CEO effective Feb. 1, to succeed Greg Summe. During the summer, he was promoted to president of the company, in which he will remain, as well as COO, from president of the Life and Analytical Sciences division.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Yep, Couple of Concerns There

Publication of He Jiankui's work on gene-edited infants would raise ethical concerns for journals, Wired and others report.

Passing on Trauma, Maybe

The New York Times reports that evidence linking trauma in one generation to epigenetic effects that influence subsequent generations may be overstated.

Told to Pause

ScienceInsider reports that US National Institutes of Health researchers were told in the fall they could not obtain new human fetal tissue.

This Week in PNAS

In PNAS this week: skin pigmentation evolution among KhoeSan, biomarkers for dengue virus progression, and more.

What's Popular?

In Proteomics & Protein Research

  1. Nanoparticle Enrichment Could Enhance Plasma Protein Biomarker Discovery

    Premium

  2. Proteogenomic Approach Identifies Candidate Tumor-Specific Antigens for Immunotherapies

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.